{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Dystrophy&page=2", "query": { "condition": "Myotonic Dystrophy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Dystrophy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T07:15:47.498Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00272883", "title": "Molecular and Genetic Studies of Congenital Myopathies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Central Core Disease", "Centronuclear Myopathy", "Congenital Fiber Type Disproportion", "Multiminicore Disease", "Myotubular Myopathy", "Nemaline Myopathy", "Rigid Spine Muscular Dystrophy", "Undefined Congenital Myopathy" ], "interventions": [], "intervention_types": [], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4000, "start_date": "2003-08", "completion_date": "2050-01", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00272883" }, { "nct_id": "NCT03692312", "title": "Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Congenital Myotonic Dystrophy" ], "interventions": [ { "name": "Tideglusib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AMO Pharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "6 Years to 16 Years" }, "enrollment_count": 56, "start_date": "2021-03-03", "completion_date": "2023-04-04", "has_results": true, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03692312" }, { "nct_id": "NCT01403402", "title": "Congenital Muscle Disease Study of Patient and Family Reported Medical Information", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)", "Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy)", "Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C))", "Alpha-Dystroglycanopathy (Fukuyama CMD)", "Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I))", "Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K))", "Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M))", "Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N))", "Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O))", "Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T))", "Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U))", "Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related)", "Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB))", "Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS))", "Choline Kinase B Receptor - CHKB", "Collagen VI Related Disorders", "Collagen XII Related Disorders", "Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive)", "Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID)", "Congenital Muscular Dystrophy With Joint Hyperlaxity", "Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1", "Emery-Dreifuss Muscular Dystrophy", "GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement", "LMNA Related Disorders", "Merosin Deficient CMD (Full or Partial)", "Nesprin Related MD (SYNE1)", "SELENON Related Disorders (Previously Known as SEPN1)", "SELENON Related Myopathy (Aka SEPN1)", "Telethonin CMD", "Congenital Myasthenic Syndrome", "Limb-Girdle Muscular Dystrophy", "LGMDD01 - DNAJB6 (Formerly LGMD1D)", "LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant)", "LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G)", "LGMDR08 - TRIM Related (Formerly LGMD2H)", "LGMDR09 - FKRP Related (Formerly LGMD2I)", "LGMDR10 - Titin (TTN) Related (Formerly LGMD2J)", "LGMDR11 - POMT1 Related (Formerly LGMD2K)", "LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M)", "LGMDR14 - POMT2 Related (Formerly LGMD2N)", "LGMDR15 - POMGnT1 Related (Formerly LGMD2O)", "LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P)", "LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q)", "LGMDR18 - TRAPPC11 Related (Formerly LGMD2S)", "LGMDR19 - GMPPB Related (Formerly LGMD2T)", "LGMDR20 - ISPD Related (Formerly LGMD2U)", "LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive)", "LGMDR23 - LAMA2 Related", "LGMDR24 - POMGnT2 Related" ], "interventions": [], "intervention_types": [], "sponsor": "Cure CMD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4000, "start_date": "2009-09", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 1, "location_summary": "Lakewood, California", "locations": [ { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403402" }, { "nct_id": "NCT07008469", "title": "Global Open-Label Extension Study of Del-desiran for the Treatment of DM1", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myotonic Dystrophy Type 1", "DM1", "Myotonic Dystrophy", "Myotonia", "Myotonic Dystrophy 1", "Myotonic Disorders", "Steinert Myotonic Dystrophy", "Steinert Disease" ], "interventions": [ { "name": "Del-desiran (AOC 1001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 230, "start_date": "2025-07-25", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 17, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07008469" }, { "nct_id": "NCT07505342", "title": "Remote Assessments and Genetic Determinants of Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myotonic Dystrophy Type 1 (DM1)", "DM1" ], "interventions": [], "intervention_types": [], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "88 Years", "sex": "ALL", "summary": "18 Years to 88 Years" }, "enrollment_count": 1000, "start_date": "2022-05-10", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07505342" }, { "nct_id": "NCT05004129", "title": "Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Congenital Myotonic Dystrophy" ], "interventions": [ { "name": "Tideglusib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AMO Pharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "6 Years to 45 Years" }, "enrollment_count": 76, "start_date": "2021-08-23", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05004129" }, { "nct_id": "NCT07700225", "title": "Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "DM1", "Myotonic Dystrophy", "Myotonic Dystrophy 1", "Myotonic Dystrophy Type 1", "Myotonic Dystrophy Type-1", "Myotonic Dystrophy, Type 1 (DM1)", "Myotonic Muscular Dystrophy" ], "interventions": [], "intervention_types": [], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1000, "start_date": "2026-07", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07700225" }, { "nct_id": "NCT04886518", "title": "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myotonic Dystrophy 1", "Excessive Daytime Sleepiness" ], "interventions": [ { "name": "Pitolisant Oral Tablet", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harmony Biosciences Management, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2021-06-28", "completion_date": "2024-10-31", "has_results": true, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 11, "location_summary": "Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886518" }, { "nct_id": "NCT07502989", "title": "Muscle Health Measurements Using Electrical Impedance Myography", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myopathy", "Muscular Dystrophies", "Myositis", "Myofibrillar Myopathy", "Congenital Myopathy", "Distal Myopathy", "Myopathies" ], "interventions": [ { "name": "Electrical Impedance Myography", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 150, "start_date": "2025-04-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07502989" }, { "nct_id": "NCT00233519", "title": "Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myotonic Dystrophy" ], "interventions": [ { "name": "SomatoKine/IPLEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "21 Years to 60 Years" }, "enrollment_count": 17, "start_date": "2005-11", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2012-06-25", "last_synced_at": "2026-07-22T07:15:47.498Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00233519" } ] }